{"id":"W2971024070","doi":"10.1182/blood.v130.suppl_1.3111.3111","title":"Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Carfilzomib; Ibrutinib; Multiple myeloma; Medicine; Lenalidomide; Pomalidomide; Dexamethasone; Refractory (planetary science); Oncology; Internal medicine; Leukemia; Chronic lymphocytic leukemia; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001624385,0.001348006,0.002006192,0.0004488257,0.000461296,0.0008784081,0.00051353,0.0007229153,0.002275179],"category_scores_gemma":[0.001490284,0.0004846483,0.001207134,0.0004081007,0.000428794,0.000692784,0.0004227305,0.00216601,0.0006471364],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001182355,"about_ca_system_score_gemma":0.001059773,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001520615,"about_ca_topic_score_gemma":0.003343819,"domain_scores_codex":[0.9994998,0.0002494303,0.00003165116,0.00007604474,0.00005202866,0.00009096954],"domain_scores_gemma":[0.9991726,0.00017776,0.0001493291,0.00006397454,0.00006175656,0.0003744987],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6611881,0.0643511,0.03579086,0.0007541982,0.002021505,0.0006346263,0.0006040892,0.004480226,0.04164981,0.0001022233,0.005809062,0.1826142],"study_design_scores_gemma":[0.282758,0.5984333,0.09850815,0.0001048948,0.001719313,0.001047799,0.0001609407,0.002103506,0.008085145,0.0001696891,0.006839916,0.00006928189],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921402,0.0031269,0.0002659106,0.000414111,0.00005625014,0.001108584,0.001162562,0.00006609922,0.001659337],"genre_scores_gemma":[0.9912432,0.001534071,0.0008951032,0.0007367056,0.0001510085,0.0008480003,0.003294732,0.00002751323,0.001269663],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002275179,"threshold_uncertainty_score":0.008590698,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02258653904098449,"score_gpt":0.3055645375472107,"score_spread":0.2829779985062262,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}